New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
07:11 EDTBLRXBioLineRx's BL-8040 for stem cell mobilization receives Orphan Drug designation
BioLineRx has received notice from the FDA confirming an Orphan Drug Designation of BL-8040 as a treatment for stem cell mobilization, in addition to the Orphan Drug Designation previously granted to BL-8040 as a treatment for Acute Myeloid Leukemia. Orphan Drug Designation entitles the sponsor to a seven-year marketing exclusivity period, clinical protocol assistance with the FDA, as well as federal grants and tax credits.
News For BLRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 27, 2015
06:13 EDTBLRXBioLineRx announces Bellerophon reported results from BCM clinical trial
Subscribe for More Information
July 16, 2015
16:34 EDTBLRXBioLineRx files $75M mixed securities shelf
Subscribe for More Information
July 15, 2015
11:55 EDTBLRXBioLineRx management to meet with JMP Securities
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use